{"entity":{"id":"allo-647","kind":"drug","name":"ALLO-647","aka":[],"tldr":"ALLO-647 is an experimental monoclonal antibody from Allogene Therapeutics in phase 2 trials for diffuse large B-cell lymphoma, aimed at CD52.","summary":"ALLO-647 is a monoclonal antibody developed by Allogene Therapeutics. Its target is CD52 (the sponsor names CD52). The sponsor states: Monoclonal antibody that recognises the CD52 antigen; used as part of a lymphodepletion regimen (with fludarabine and cyclophosphamide) ahead of allogeneic CAR T-cell dosing. ClinicalTrials.gov describes the intervention as: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in diffuse large B-cell lymphoma. The largest, NCT04416984, plans to enrol 160 participants with primary completion expected 2029-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of ALLO-647","url":"https://clinicaltrials.gov/search?intr=ALLO-647"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":["cd52"],"drugs":[],"companies":["allogene"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04416984"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"Monoclonal antibody that recognises the CD52 antigen; used as part of a lymphodepletion regimen (with fludarabine and cyclophosphamide) ahead of allogeneic CAR T-cell dosing.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/allo-647/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"target":[{"id":"cd52","kind":"target","name":"CD52","route":"/targets/cd52/"}],"company":[{"id":"allogene","kind":"company","name":"Allogene Therapeutics","route":"/companies/allogene/"}],"trial":[{"id":"nct04416984","kind":"trial","name":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","route":"/trials/nct04416984/"}]}}